February 23, 2017 06:26 AM EST
Pharma

The FDA opens an in­side track to let No­var­tis race ahead on Zyka­dia as Roche ri­val­ry heats up

John Carroll

Editor & Founder

No­var­tis just leaped for­ward with its can­cer drug Zyka­dia (cer­i­tinib), gain­ing a pri­or­i­ty re­view from the FDA as a front­line treat­ment for ALK-pos­i­tive non …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times